Medigen Biotechnology (ROCO:3176) Cyclically Adjusted Revenue per Share: NT$9.67 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:3176 Medigen Biotechnology Corp ROCO:3176
55 GF Score
Price NT$31.65
GF Value NT$36.83
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Medigen Biotechnology Cyclically Adjusted Revenue per Share?

Medigen Biotechnology ROCO:3176 +1.61% 55 Cyclically Adjusted Revenue per Share is NT$9.67 as of Mar. 2026. GuruFocus rates ROCO:3176 with a GF Score™ of 55/100 and a GF Value™ of NT$36.83 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Medigen Biotechnology's adjusted revenue per share for the three months ended in Mar. 2026 was NT$1.870. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$9.67 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Medigen Biotechnology's average Cyclically Adjusted Revenue Growth Rate was 10.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 12.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 24.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Medigen Biotechnology was 42.40% per year. The lowest was 12.60% per year. And the median was 39.80% per year.

As of today (2026-08-04), Medigen Biotechnology's current stock price is NT$31.65. Medigen Biotechnology's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was NT$9.67. Medigen Biotechnology's Cyclically Adjusted PS Ratio of today is 3.27.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Medigen Biotechnology was 40.16. The lowest was 3.07. And the median was 6.27.


Medigen Biotechnology  (ROCO:3176) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Medigen Biotechnology's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=31.65/9.67
=3.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Medigen Biotechnology was 40.16. The lowest was 3.07. And the median was 6.27.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Medigen Biotechnology Cyclically Adjusted Revenue per Share Related Terms


Medigen Biotechnology Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Medigen Biotechnology's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigen Biotechnology Cyclically Adjusted Revenue per Share Chart

Medigen Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.57 6.59 7.57 8.40 9.41

Medigen Biotechnology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.79 9.03 9.29 9.41 9.67

ROCO:3176 vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Medigen Biotechnology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigen Biotechnology Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medigen Biotechnology's Cyclically Adjusted PS Ratio falls into.


ROCO:3176
55GF Score
Medigen Biotechnology Corp ROCO:3176
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigen Biotechnology Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medigen Biotechnology's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.87/330.2130*330.2130
=1.870

Current CPI (Mar. 2026) = 330.2130.

Medigen Biotechnology Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.751 241.018 1.029
201609 0.718 241.428 0.982
201612 0.665 241.432 0.910
201703 0.732 243.801 0.991
201706 0.834 244.955 1.124
201709 0.758 246.819 1.014
201712 0.758 246.524 1.015
201803 0.791 249.554 1.047
201806 0.789 251.989 1.034
201809 0.716 252.439 0.937
201812 0.647 251.233 0.850
201903 0.766 254.202 0.995
201906 1.205 256.143 1.553
201909 0.802 256.759 1.031
201912 1.222 256.974 1.570
202003 0.943 258.115 1.206
202006 1.010 257.797 1.294
202009 1.101 260.280 1.397
202012 1.359 260.474 1.723
202103 1.334 264.877 1.663
202106 1.258 271.696 1.529
202109 10.016 274.310 12.057
202112 15.651 278.802 18.537
202203 3.485 287.504 4.003
202206 1.373 296.311 1.530
202209 1.272 296.808 1.415
202212 1.464 296.797 1.629
202303 1.180 301.836 1.291
202306 1.478 305.109 1.600
202309 3.009 307.789 3.228
202312 2.651 306.746 2.854
202403 1.806 312.332 1.909
202406 2.371 314.175 2.492
202409 3.081 315.301 3.227
202412 2.373 315.605 2.483
202503 3.607 319.799 3.724
202506 2.562 322.561 2.623
202509 2.875 324.800 2.923
202512 2.345 324.054 2.390
202603 1.870 330.213 1.870

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$9.67 mean?
Medigen Biotechnology (ROCO:3176) has a Cyclically Adjusted Revenue per Share of NT$9.67 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medigen Biotechnology and its competitors.
Is Medigen Biotechnology's Cyclically Adjusted Revenue per Share too high?
Medigen Biotechnology's current Cyclically Adjusted Revenue per Share is NT$9.67. Overall, Medigen Biotechnology has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Medigen Biotechnology's Cyclically Adjusted Revenue per Share of NT$9.67 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medigen Biotechnology and its competitors. Medigen Biotechnology's current Cyclically Adjusted Revenue per Share is NT$9.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$36.83, compared to a current price of NT$31.65 — trading 14.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$9.67. Medigen Biotechnology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current Cyclically Adjusted Revenue per Share is NT$9.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?

Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be undervalued. The current stock price of NT$31.65 is trading 14.1% below its estimated GF Value™ of NT$36.83. GuruFocus considers Medigen Biotechnology to be Modestly Undervalued.

Key valuation signals for ROCO:3176:

  • Cyclically Adjusted Revenue per Share: NT$9.67
  • GF Value™: NT$36.83 vs. price of NT$31.65 (14.1% below fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medigen Biotechnology Business Description

Address Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
55GF Score

Get the complete analysis for ROCO:3176

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.65
Price
NT$36.83
GF Value